HOME
• drugs effexor xr
• herbal interations with effexor xl
• combining prozac with effexor
• dosage for effexor

zoloft or effexor

Venlafaxine can pass into breast milk and may harm a nursing baby. While Effexor has not been systematically studied in clinical trials for its potential for abuse, there was no indication of drug-seeking behavior in the clinical trials. The zoloft or effexor period to observe patients for relapse, zoloft or effexor as a CGI Severity of Illness item score ≥4, was for up to 52 weeks. Call your doctor for medical advice about side effects. Labor and Delivery The effect of EffexorŽ (venlafaxine hydrochloride) on labor and delivery in humans is unknown. Altered anticoagulant effects, including zoloft or effexor bleeding, have been reported when SSRIs and SNRIs are coadministered with warfarin.

Go To...

• effexor worsens depression
• tapering off of effexor
• zoloft versus effexor
• class action lawsuit against wyeth effexor
• surdosage effexor

zoloft or effexor

Tachycardia and QTc prolongation appear to occur in a dose-dependent manner. In one case report, venlafaxine (75 mg 3 times/day) may have contributed to an elevation in defibrillation threshold in a patient with nonischemic cardiomyopathy and an implantable cardioverter- defibrillator. In addition, at least one case of photo-induced telangiectasia has been associated with venlafaxine use. Other Other side effects have frequently included asthenia (up to 21%), headache (up to 34%), flu syndrome (6%), and accidental injury (5%). Other side effects reported in premarketing Phase 3 trials have included edema, hyperacusis, otitis media, parosmia, loss of taste, deafness, labyrinthitis, otitis externa, substernal chest pain, chills, fever, neck pain, face edema, intentional injury, malaise, moniliasis, neck rigidity, pelvic pain, photosensitivity reaction, suicide attempt, appendicitis, bacteremia, carcinoma, and cellulitis. Withdrawal symptoms were reported to include brief bursts of dizziness associated with headache, anxiety, irritability, agitation, insomnia, paresthesias, nausea, vomiting, diarrhea, tremor, fatigue, sweating, and worsening of depression (similar to symptoms reported after withdrawal from selective serotonin reuptake inhibitors). Although zoloft or effexor zoloft or effexor occurred during treatment with venlafaxine, causality has not been determined. Ocular Ocular side effects have included abnormal vision, primarily blurred vision, in approximately 6% of patients. Hyponatremia tends to develop within the first few weeks of treatment zoloft or effexor 3 to 120 days) and zoloft or effexor resolves within 2 weeks (range 48 hours to 6 weeks) after therapy has been discontinued with some patients requiring treatment. Following discontinuation of therapy the amount of REM sleep tends to rebound. Clinically relevant increases in serum cholesterol, defined as 1) a final on-therapy increase in serum cholesterol ≥50 mg/dL from baseline and to a value ≥261 mg/dL or 2) an average on‑therapy increase in serum cholesterol ≥50 mg/dL from baseline and to a value ≥261 mg/dL, were recorded in 5.3% of venlafaxine-treated patients and 0.0% of placebo-treated patients. ECG Changes In an analysis of ECGs obtained in 769 patients treated with Effexor and 450 patients treated with placebo in controlled clinical trials, the only statistically significant difference observed was for heart rate, ie, a mean increase from baseline of 4 beats per minute for Effexor. Clinically relevant increases in serum cholesterol, defined as 1) a final on-therapy increase in serum cholesterol ≥50 mg/dL from baseline and to a value ≥261 mg/dL zoloft or effexor 2) an average on‑therapy increase in serum cholesterol ≥50 mg/dL from zoloft or effexor and zoloft or effexor a value ≥261 mg/dL, were recorded in 5.3% of venlafaxine-treated patients and 0.0% of placebo-treated patients. ECG Changes In an analysis of ECGs obtained in 769 patients zoloft or effexor with Effexor and 450 patients treated zoloft or effexor placebo in controlled clinical trials, the only statistically significant difference observed was for heart rate, ie, a mean increase from baseline of 4 beats per minute for Effexor. In all cases, hair re- growth occurred zoloft or effexor 2 to 4 weeks following discontinuation of venlafaxine. Dermatologic side effects have included sweating in up to approximately 14% of treated patients. Although these events occurred during treatment with venlafaxine, causality has not been determined. There is a zoloft or effexor case report of breast zoloft or effexor associated with venlafaxine therapy. Dermatologic At least 3 cases of venlafaxine- induced alopecia have been reported. Although these events zoloft or effexor during treatment with venlafaxine, causality has not been determined. Musculoskeletal Musculoskeletal side effects have included rhabdomyolysis. Musculoskeletal side effects reported in premarketing Phase 3 trials have included arthralgia, arthritis, arthrosis, bone spurs, bursitis, leg cramps, myasthenia, tenosynovitis, bone pain, pathological fracture, muscle cramp, muscle spasms, musculoskeletal stiffness, myopathy, osteoporosis, osteosclerosis, plantar fasciitis, rheumatoid arthritis, and tendon rupture. In the event that therapy is not reintroduced, withdrawal symptoms may last from 5 to 7 days before resolving spontaneously. In one case report, withdrawal- induced full mania developed in a 33- year- old patient following abrupt termination of treatment with venlafaxine extended-release (150 mg daily for 10 weeks). Hepatic Hepatic side effects have included toxic hepatitis. If the COSTART term for an event was so general as to be uninformative, it was replaced with a more informative term. In one case, toxic hepatitis associated with low dose (37.5 zoloft or effexor venlafaxine was reported in a patient with a history of chronic hepatitis. Endocrine Endocrine side effects have included flushing. Endocrine side effects reported in premarketing Phase 3 trials have rarely included galactorrhea, zoloft or effexor hyperthyroidism, hypothyroidism, thyroid nodule, and thyroiditis. The frequencies presented, therefore, represent the proportion of the 5356 patients exposed to multiple doses of either formulation zoloft or effexor venlafaxine who experienced an event of the type cited on at least one occasion while receiving venlafaxine. The onset of withdrawal symptoms ranges from 14 to 48 hours after the last dose of venlafaxine extended-release and symptoms tend to resolve rapidly (range, within 2 to 24 hours) after resumption of therapy. Experience with the immediate-release venlafaxine showed that zoloft or effexor hypertension was zoloft or effexor increasing from 3% to 7% at 100 to 300 mg/day to 13% at doses above 300 mg/day. Although these events occurred during treatment with venlafaxine, causality has not been determined. There is a single case report of breast pain associated with venlafaxine therapy. Dermatologic At least 3 cases of venlafaxine- induced alopecia have been reported. Although these events occurred during treatment with venlafaxine, causality has not been determined. Impaired coordination and balance have been reported in postmarketing studies. Seizures have been reported in zoloft or effexor of treated patients during premarketing testing. Clinically relevant increases in serum cholesterol, defined as 1) a final on-therapy increase in serum cholesterol ≥50 mg/dL from baseline and to a value ≥261 mg/dL or 2) an average on‑therapy increase in serum cholesterol ≥50 mg/dL from baseline and to a value ≥261 mg/dL, were recorded in 5.3% of venlafaxine-treated patients and 0.0% of placebo-treated patients. ECG Changes In an analysis of ECGs obtained in 769 patients treated with Effexor and 450 patients treated with placebo in controlled clinical trials, the only statistically significant difference observed was for heart rate, ie, a mean increase from baseline of 4 beats per minute for Effexor. Although these events occurred during treatment with venlafaxine, causality has not been determined. Impaired coordination and balance have been reported in postmarketing studies. Seizures have been reported in 0.26% of treated patients during premarketing testing. The frequencies presented, therefore, represent the proportion of the 5356 patients exposed to multiple doses of either formulation of venlafaxine who zoloft or effexor an event of the type cited on at least one occasion while receiving venlafaxine. The reduction in REM sleep is greatest early in treatment, but gradually returns towards baseline during zoloft or effexor therapy; however, ROL remains long.